Skip to main content

CORRECTION article

Front. Pharmacol., 09 October 2018
Sec. Experimental Pharmacology and Drug Discovery
Volume 9 - 2018 | https://doi.org/10.3389/fphar.2018.01128

Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR

This article is a correction to:

  1. Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR

    1. Read original article
\r\nJun-ming Huang&#x;Jun-ming Huang†Ran-yue Ren&#x;Ran-yue Ren†Yuan BaoYuan BaoJia-chao GuoJia-chao GuoWei XiangWei XiangXing-zhi JingXing-zhi JingJia ShiJia ShiGuo-xiang ZhangGuo-xiang ZhangLong LiLong LiYong TianYong TianHao Kang*Hao Kang*Feng-jin Guo*Feng-jin Guo*
  • Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

A Corrigendum on
Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR

by Huang, J., Ren, R., Bao, Y., Guo, J., Xiang, W., Jing, X., et al. (2018). Front. Pharmacol. 9:1016. doi: 10.3389/fphar.2018.01016

In the original article, there was a mistake in Figure 1 as published. The images used for the group of OVX+U were from a different study. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

FIGURE 1
www.frontiersin.org

Figure 1. Ulinastatin inhibits bone loss induced by OVX. (A) μ-CT images of the trabecular bone of distal femoral metaphysis from the SHAM, OVX, and OVX + ulinastatin groups. (B) The trabecular structural parameters of the distal femur: trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp). Data are presented as means ± SD. n = 10 and *P < 0.05.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: ulinastatin, uPAR, osteoclast, MAPKs, NF-kB, RANKL, osteoporosis

Citation: Huang J, Ren R, Bao Y, Guo J, Xiang W, Jing X, Shi J, Zhang G, Li L, Tian Y, Kang H and Guo F (2018) Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR. Front. Pharmacol. 9:1128. doi: 10.3389/fphar.2018.01128

Received: 07 September 2018; Accepted: 14 September 2018;
Published: 09 October 2018.

Edited and reviewed by: Wolff Mayer Kirsch, Loma Linda University Medical Center (LLUMC), United States

Copyright © 2018 Huang, Ren, Bao, Guo, Xiang, Jing, Shi, Zhang, Li, Tian, Kang and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hao Kang, kanghao100@vip.sina.com
Feng-jin Guo, fguo@tjh.tjmu.edu.cn

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.